Mechanism of Action: From Enzyme Inhibition to Cell Death
The basis of azole action is a profound disruption of the ergosterol synthesis cascade. Normally, this multi-step process begins with acetyl-CoA molecules, progressing through mevalonic acid to synthesize squalene. Squalene is then converted into lanosterol, which is sequentially transformed into zymosterol, fecosterol, and finally, mature ergosterol.
Azoles act at the step where lanosterol is transformed. They bind tightly to the iron atom in the heme of the 14-α-demethylase enzyme (a cytochrome P-450 system enzyme) and inactivate it. This triggers a cascade of biochemical consequences that are lethal to the fungus:
- Ergosterol synthesis is completely blocked.
- Toxic precursors—lanosterol and 14α-methylsterols—accumulate in excess within the cell.
- The accumulated methylsterols physically disrupt the tight packing of phospholipid acyl chains in the membrane.
- The membrane becomes destabilized, leading to dysfunction of membrane-bound enzymes (including the electron transport chain). The ultimate outcome is the inevitable death of the fungal cell.
Classification and Spectrum of Activity
Based on the chemical structure of the heterocyclic ring, the entire group is divided into two major categories:
- Imidazoles. Contain a five-membered ring with two nitrogen atoms. This subgroup includes ketoconazole, clotrimazole, miconazole, econazole, butoconazole, oxiconazole, sertaconazole, and sulconazole.
- Triazoles. Contain a five-membered ring with three nitrogen atoms. A typical representative often shown in diagrams is fluconazole.
These drugs exhibit a broad spectrum of activity and are available in formulations for both systemic and topical use. They are highly effective against candidiasis, aspergillosis, cryptococcosis, dermatophytoses, and severe endemic infections (blastomycosis, histoplasmosis, coccidioidomycosis, and paracoccidioidomycosis). An important clinical advantage of this group is that resistance in pathogenic fungi develops rarely.
Selectivity Issues and Drug Interactions
Azoles lack absolute selectivity. Because their target is a heme-containing enzyme of the cytochrome P-450 system, they can inhibit analogous human hepatic isoenzymes responsible for the metabolism of various xenobiotics.
A clear clinical example of a dangerous interaction is the combination with the immunosuppressant cyclosporine. It is prescribed to kidney, liver, or heart transplant recipients to prevent graft rejection. Cyclosporine is metabolized by hepatic P-450 enzymes and excreted in the bile. If systemic azoles are co-administered to such a patient, the metabolism of the immunosuppressant is sharply delayed. Its blood concentration rises to toxic levels, risking severe nephrotoxicity and hepatotoxicity. In such cases, a mandatory dose reduction of cyclosporine and strict therapeutic drug monitoring are required.
Side Effects of Systemic Therapy
The toxicity profile of systemically administered azoles is broad and affects multiple body systems simultaneously:
- Endocrine System: Cytochrome P-450 enzymes participate in the synthesis of human steroid hormones. Azoles can block the 17,20-desmolase enzyme, which is required for the biosynthesis of testosterone and corticosteroids. This produces a pronounced anti-androgen effect: men may develop gynecomastia, oligospermia, and impotence, while women experience menstrual cycle irregularities. This is why modern drugs require high selectivity for fungal demethylase.
- Hepatobiliary System: Direct hepatotoxicity is characteristic.
- Central Nervous System: General cerebral manifestations (somnolence, dizziness, headache) and focal neurological signs (paresthesias, tremor, seizures) are possible.
- Hematopoietic System: There is a risk of developing hemolytic anemia and thrombocytopenia.
- Gastrointestinal Tract and Allergic Reactions: Dyspeptic disorders (nausea, vomiting, anorexia) are frequent, along with skin rashes, urticaria, and drug-induced fever.